We then overexpressed CSF-1 in epithelial 4NQO-L cells and evaluated the tumor response to trametinib in vivo, including profiling the number of MDSCs expressing CD11c+ and CD8+ T cells in the tumor. The gene discussed is CD8A; the disease is neoplasm.